Association between IL-10 gene polymorphisms (− 1082 A/G, -819 T/C, -592 A/C) and hepatocellular carcinoma: a meta-analysis and trial sequential analysis
Mei, Teresa Tan Yen, Aung, Htar Htar, Tung, Wong Siew, and Naing, Cho (2023) Association between IL-10 gene polymorphisms (− 1082 A/G, -819 T/C, -592 A/C) and hepatocellular carcinoma: a meta-analysis and trial sequential analysis. BMC Cancer, 23. 842.
|
PDF (Published Version)
- Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Background: The carcinogenesis of hepatocellular carcinoma is complicated, and genetic factor may have the role in the malignant transformation of liver cells. IL-10 gene polymorphisms have been investigated for their potential roles in hepatocellular carcinoma This study aimed to investigate the relationship between polymorphisms of IL-10 (-1082 A/G, -819 T/C, -592 A/C), and hepatocellular carcinoma by performing a meta-analysis with eligible individual studies.
Methods: This study followed the PRISMA 2020 Checklist. Relevant studies were searched in health-related databases. The Newcastle-Ottawa Scale criteria were used to evaluate the studies quality. Pooled odds ratio (OR) and its 95% confidence interval (CI) were used to determine the strength of association between each polymorphism and hepatocellular carcinoma using five genetic models. Stratification was done by ethnic groups. Trial sequential analysis (TSA) was performed to determine the required information size.
Results: Fifteen case-control studies (n = 8182) were identified. Overall, the heterozygous model showed a marginal significant association only between IL-10 (-1082 A/G) and hepatocellular carcinoma risk (OR: 0.82, 95% CI: 0.67-1.00, 9 studies). On stratification, IL-10 (-1082 A/G) was significantly associated with hepatocellular carcinoma risk in the non-Asian population under dominant (OR: 0.62, 95% CI: 0.45–0.86, 4 studies), heterozygous (OR: 0.60, 95% CI: 0.43–0.85) and allelic models (OR: 0.79, 95% CI: 0.64–0.99). IL-10 (-819 T/C) was significantly associated with hepatocellular carcinoma risk only among non-Asians under the dominant (OR: 1.47, 95% CI: 1.02–2.13, 8 studies), recessive (OR: 1.99, 95% CI: 1.03–3.86, and homozygous models (OR: 2.18, 95% CI: 1.13–4.23). For IL-10 (-592 A/C) with 11 studies, there was no significant association with hepatocellular carcinoma in all five genetic models (P values > 0.5). TSA plots indicated that the information size for firm evidence of effect was sufficient only for the analysis of IL-10 (-592 A/C), but not for the − 1082 A/G or -819 T/C.
Conclusions: Findings suggest that IL-10 (-1082 A/G and − 819 T/C) polymorphisms are associated with hepatocellular carcinoma in ethnic-specific manner. However, this evidence is not conclusive because the sample size was insufficient. IL-10 (-592 A/C) polymorphism was not associated with hepatocellular carcinoma albeit with sufficient information size. Future well-designed large case-control studies on IL-10 (-1082 A/G and − 819 T/C) with different ethnicities are recommended.
Item ID: | 80510 |
---|---|
Item Type: | Article (Research - C1) |
ISSN: | 1471-2407 |
Keywords: | Genetic association, Hepatocellular carcinoma, IL-10 gene polymorphisms, meta-analysis, Trial sequential analysis |
Copyright Information: | © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
Date Deposited: | 12 Feb 2024 22:16 |
FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3211 Oncology and carcinogenesis > 321103 Cancer genetics @ 100% |
SEO Codes: | 20 HEALTH > 2001 Clinical health > 200104 Prevention of human diseases and conditions @ 100% |
Downloads: |
Total: 44 Last 12 Months: 4 |
More Statistics |